Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp
Go

Health Care : Biotechnology | Large Cap Value

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price: $63.08

Day's Change: 0.50 (0.80%)

Bid: --

Ask: --

B/A Size: --

Day's High: 63.13

Day's Low: 61.85

Volume (Average) Volume: 9,207,746 10-day average volume: 8,707,700: 9,207,746

Freeport-McMoRan Inc. Stock Falls Friday, Underperforms Market

4:52 pm ET April 22, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Freeport-McMoRan Inc. (FCX) slipped 6.76% to $41.91 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 2.77% to 4,271.78 and Dow Jones Industrial Average falling 2.82% to 33,811.40. This was the stock's fourth consecutive day of losses. Freeport-McMoRan Inc. closed $10.08 below its 52-week high ($51.99), which the company achieved on March 25th.

Trading volume (31.6 M) eclipsed its 50-day average volume of 17.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled April 22, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

April 22, 2022 16:52 ET (20:52 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and